Nuvectis Pharma
- | Biotech or pharma, therapeutic R&D
Nuvectis Pharma (NVCT) oncology pipeline includes: 1) NXP800 - ongoing single single-agent clinical studies in patients with platinum-resistant, ARID1a-mutated ovarian cancer and cholangiocarcinoma; 2) NXP900, a novel YES1/SRC kinase inhibitor in phase 1.
Address
Fort LeeNJ
United States
)
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}
)
){kind=logo}
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}
){kind=logo}